Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population

Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population

Abstract Background Biliary tract cancers (BTCs) are a heterogeneous group of malignant cancers with an overall poor prognosis. For more than a decade, the standard palliative first-line therapy was cytotoxic chemotherapy with gemcitabine/cisplatin. The results of the TOPAZ-1 and KEYNOTE-966 trials...

Full description

Saved in:
Bibliographic Details
Main Authors: Florian Gerhardt, Christian Müller, Marino Venerito, Jack Chater, Raphael Mohr, Mara Egerer, Udo Lindig, Aaron Schindler, Sebastian Ebel, Janett Fischer, Maik Schwarz, Sonja Gehring, Thomas Berg, Florian van Bömmel
Format: Article
Language:English
Published: Springer 2025-06-01
Series:Journal of Cancer Research and Clinical Oncology
Subjects:
Cholangiocarcinoma
Biliary tract cancer
Liver cancer
Immune checkpoint inhibitor
Real-world data
Online Access:https://doi.org/10.1007/s00432-025-06239-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00432-025-06239-1

Similar Items